Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

References

• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed. Cephalalgia 2018;38:1-211
   PubMed Web of Science ®Google Scholar
• Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994;309:765-9
   PubMed Web of Science ®Google Scholar
• Mavromichalis I, Anagnostopoulos D, Metaxas N, et al. Prevalence of migraine in schoolchildren and some clinical comparisons between migraine with and without aura. Headache 1999;39:728-36
   PubMedGoogle Scholar
• Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013;53:1278-99
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010;11:289-99
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015;55:21-34
   Google Scholar
• Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
   PubMed Web of Science ®Google Scholar
• Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994;44(6Suppl4):S17-23
   Web of Science ®Google Scholar
• Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609
   PubMed Web of Science ®Google Scholar
• Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013;53:413-19
   PubMed Web of Science ®Google Scholar
• Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52:930-45
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015;35:478-88
   PubMed Web of Science ®Google Scholar
• Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health 2009;12:55-64
   PubMed Web of Science ®Google Scholar
• Serrano D, Manack AN, Reed ML, et al. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health 2013;16:31-8
   PubMed Web of Science ®Google Scholar
• Freitag FG, Lyss H, Nissan GR. Migraine disability, healthcare utilization, and expenditures following treatment in a tertiary headache center. Proc Bayl Univ Med Cent 2013;26:363-7
   PubMedGoogle Scholar
• Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017;377:2123-32
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425-34
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s) [Abstract]. Cephalalgia 2017;37:13-14
   Web of Science ®Google Scholar
• Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ 2017;20:555-64
   PubMed Web of Science ®Google Scholar
• Turner IM, Newman SM, Entin EJ, et al. Prophylactic treatment of migraine with botulinum toxin type A: a pharmacoeconomic analysis in a community setting. J Med Econ 2007;10:355-66
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093-103
   PubMed Web of Science ®Google Scholar
• Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52:1456-70
   PubMed Web of Science ®Google Scholar
• Ashina M, Tepper S, Brandes JL, et al. Efficacy of erenumab (a fully human Mab targeting the CGRP receptor) in chronic migraine patients with prior treatment failure: a subgroup analysis of the phase 2, randomized, double-blind, placebo-controlled study. Cephalalgia 2017;37:326-8
   Web of Science ®Google Scholar
• Couch JR Jr. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology 1987;6:178-85
   PubMed Web of Science ®Google Scholar
• Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2016;65:1-122
   Google Scholar
• Amgen Data on File. Amgen; 2017. Thousand Oaks, CA: Amgen Data on File. Amgen Inc.
   Google Scholar
• Porter J, Brennan A, Palmer S, et al. Parametric simulation of headache day frequency using a negative binomial distribution: a case study of erenumab in episodic migraine. Value Health 2016;7:A361
   Google Scholar
• Porter J, Brennan A, Palmer S, et al., editors. Modeling migraine day frequency using the beta-binomial distribution: a case study of erenumab as migraine prophylaxis. Value in health. New York, NY: Elsevier Science Inc; 2017
   Google Scholar
• Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2009;49:498-508
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. CMS Physician Fee Schedule. 7500 Security Boulevard, Baltimore, MD 21244. United States, 2016
   Google Scholar
• Centers for Medicare and Medicaid Services. CMS Acute Inpatient Prospective Payment System. 7500 Security Boulevard, Baltimore, MD 21244. United States, 2016.
   Google Scholar
• Amgen Data on File. Truven Health MarketScan US Claims database analysis. Amgen Inc. Thousand Oaks, CA. 2017.
   Google Scholar
• Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 2009;29:891-7
   PubMed Web of Science ®Google Scholar
• Lohman JJ, van der Kuy-de Ree MM, Group of Co-operating Pharmacists Sittard-Geleen and its environs. Patterns of specific antimigraine drug use—a study based on the records of 18 community pharmacies. Cephalalgia 2005;25:214-18
   PubMed Web of Science ®Google Scholar
• Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T 2008;33:404-16
   PubMedGoogle Scholar
• Batty AJ, Hansen RN, Bloudek LM, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 2013;16:877-87
   PubMedGoogle Scholar
• Bureau of Labor Statistics, U.S. Department of Labor, Occupational Employment and Wages, December 2016, Bulletin USDL-17-0059, U.S. Government Printing Office, Washington, DC, 2017. Available from: https://www.bls.gov/news.release/archives/realer_01182017.pdf
   Google Scholar
• Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000;88:41-52
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Bonner J, Broessner G, et al. Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial. Journal of Neurology, Neurosurgery & Psychiatry 2017;88:e1
   PubMed Web of Science ®Google Scholar
• Gillard PJ, Devine B, Varon SF, et al. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health 2012;15:485-94
   PubMed Web of Science ®Google Scholar
• Yu J, Smith KJ, Brixner DI. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs 2010;24:695-712
   PubMed Web of Science ®Google Scholar
• Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005;45:1012-22
   PubMed Web of Science ®Google Scholar
• Lipton RB, Porter JK, Shah N, et al. A comparison of approaches to model migraine day frequency in migraine. Cephalalgia 2017;37:102-3
   Web of Science ®Google Scholar
• Brandes JL. The migraine cycle: patient burden of migraine during and between migraine attacks. Headache 2008;48:430-41
   PubMed Web of Science ®Google Scholar